At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $253.11, up 4.69%. An important factor to consider is whether the stock is rising or falling in short-term value. The ALNY shares have gain 8.60% over the last week, with a monthly amount drifted -4.45%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on November 12, 2024, when Wolfe Research downgraded its rating to a Underperform. On August 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $370 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $173 on February 16, 2024. Wolfe Research initiated its recommendation with a Peer Perform. Wells Fargo started tracking with a Equal Weight rating for this stock on December 08, 2023, and assigned it a price target of $171. In a note dated December 08, 2023, Wells Fargo initiated an Equal Weight rating.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $141.98 and $304.39. Currently, Wall Street analysts expect the stock to reach $317.67 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $253.11 at the most recent close of the market. An investor can expect a potential return of 25.51% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.25B for trailing twelve months, which represents an 34.90% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.08%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is 9.05 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of19.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 244.93 points at the first support level, and at 236.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 257.29, and for the 2nd resistance point, it is at 261.48.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 2.78. On the other hand, the Quick Ratio is 2.71, and the Cash Ratio is 0.81. Considering the valuation of this stock, the price to sales ratio is 14.57, the price to book ratio is 487.80.
Transactions by insiders
Recent insider trading involved Fitzgerald Kevin Joseph, CSO & EVP, Head of Research, that happened on Mar 03 ’25 when 1911.0 shares were sold. CSO & EVP, Head of Research, Fitzgerald Kevin Joseph completed a deal on Mar 04 ’25 to sell 844.0 shares. Meanwhile, EVP, Chief Commercial Officer Tanguler Tolga sold 471.0 shares on Mar 03 ’25.
